# Diamant Thaçi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/diamant-thaci/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,742 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 73 |
| i10-index | 252 |
| Last Known Institution | Novartis (Switzerland) |
| OpenAlex ID | https://openalex.org/A5085831636 |
| ORCID iD | https://orcid.org/0000-0001-8513-550X |
| Works | 707 |

## Researcher papers

Showing 12 of 14.

- [Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/dupilumab-treatment-in-adults-with-moderate-to-severe-atopic-dermatitis/)
- [Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adults-with-moderate-to-severe-atopic/)
- [Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials](https://scholariq.org/papers/once-daily-upadacitinib-versus-placebo-in-adolescents-and-adults-with-moderate/)
- [Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials](https://scholariq.org/papers/tildrakizumab-versus-placebo-or-etanercept-for-chronic-plaque-psoriasis/)
- [Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t](https://scholariq.org/papers/dupilumab-with-concomitant-topical-corticosteroid-treatment-in-adults-with/)
- [Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis](https://scholariq.org/papers/abrocitinib-versus-placebo-or-dupilumab-for-atopic-dermatitis/)
- [Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis](https://scholariq.org/papers/phase-2-trial-of-selective-tyrosine-kinase-2-inhibition-in-psoriasis/)
- [Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial](https://scholariq.org/papers/ixekizumab-for-the-treatment-of-patients-with-active-psoriatic-arthritis-and-an/)
- [Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-with-concomitant-topical-corticosteroids-in/)
- [Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial](https://scholariq.org/papers/deucravacitinib-versus-placebo-and-apremilast-in-moderate-to-severe-plaque/)
- [Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-lebrikizumab-for-moderate-to-severe-atopic-dermatitis/)
- [Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study](https://scholariq.org/papers/dupilumab-shows-long-term-safety-and-efficacy-in-patients-with-moderate-to/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)

## Researcher university

- [Novartis (Switzerland)](https://scholariq.org/institutions/novartis-switzerland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.